Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Senaparib + Temozolomide |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Senaparib | IMP-4297|IMP4297|IMP 4297 | PARP Inhibitor (Pan) 29 | Senaparib (IMP-4297) inhibits PARP1 and PARP2, potentially leading to anti-tumor activity (PMID: 38920409). | |
| Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06617923 | Phase II | Senaparib + Temozolomide | Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer | Recruiting | USA | 0 |
| NCT04434482 | Phase I | Senaparib + Temozolomide | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | Completed | USA | AUS | 3 |